SOFWF.US SofWave Medical Ltd.
- Market cap
- USD 416M
- P/E
- 39.4x
- P/B
- 9.77x
- ROE
- 24.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SOFWF.US undervalued?
Graham numberThe Graham number of SofWave Medical Ltd. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SofWave Medical Ltd. fundamental analysis
No fundamental analysis for SofWave Medical Ltd. yet.
SofWave Medical Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SofWave Medical Ltd.
SofWave Medical Ltd. engages in the development, production, marketing, and distribution of non-invasive medical technology for skin firming and rejuvenation, tissue renewal, treatment of muscle, aging, and other physiological change in Israel, the United States, Europe, Southeast Asia, the Middle East, and internationally. The company offers an ultrasound technology that induces coagulation and subsequent revitalization for regenerated skin under the SUPERB brand; and non-i…
Full company profileSofWave Medical Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SofWave Medical Ltd. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 35.6M | 50.3M | 59.7M | 87.6M | 110M |
| Gross Profit | 26.3M | 37.5M | 45.3M | 66.0M | 84.1M |
| Operating Income | -17.3M | -7.99M | -3.58M | 6.87M | 11.9M |
| EBITDA | -17.5M | -6.61M | -2.19M | 7.61M | 15.4M |
| Net Income | -19.5M | -8.28M | -4.55M | 5.49M | 10.5M |
| EPS | -0.56 | -0.24 | -0.13 | 0.15 | 0.29 |
| Balance Sheet | |||||
| Total Assets | 46.1M | 43.5M | 43.0M | 55.8M | 66.0M |
| Total Liabilities | 13.7M | 17.2M | 18.5M | 23.1M | 23.4M |
| Shareholders' Equity | 32.3M | 26.3M | 24.5M | 32.7M | 42.6M |
| Cash & Short-term Investments | 32.0M | 24.4M | 21.6M | 34.8M | 30.9M |
| Cash Flow | |||||
| Operating Cash Flow | -10.7M | -6.31M | -2.40M | 13.3M | 7.58M |
| Capital Expenditure | 447K | 407K | 277K | 534K | 669K |
| Free Cash Flow | -11.1M | -6.71M | -2.67M | 12.8M | 6.91M |
| Ratios | |||||
| ROE | -60.4% | -31.4% | -18.5% | 16.8% | 24.6% |
| ROA | -42.4% | -19.0% | -10.6% | 9.8% | 15.9% |
| Net Profit Margin | -54.8% | -16.5% | -7.6% | 6.3% | 9.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SofWave Medical Ltd. dividends
SofWave Medical Ltd. has not paid dividends in the last 4 fiscal years.
Who owns SofWave Medical Ltd.
- Insiders 39.34%
- Institutions 28.83%
- Public & others 31.83%
- Shares outstanding 36.4M
- Free float 17.4M
SofWave Medical Ltd. company profile
- Company name
- SofWave Medical Ltd.
- Ticker
- SOFWF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 151
- Fiscal year end
- December
- Address
- 1 Hatzma Street, Yokneam Illit, Israel, 2069500
- Phone
- 972 73 201 7650
- Website
- sofwave.com
About SofWave Medical Ltd.
SofWave Medical Ltd. engages in the development, production, marketing, and distribution of non-invasive medical technology for skin firming and rejuvenation, tissue renewal, treatment of muscle, aging, and other physiological change in Israel, the United States, Europe, Southeast Asia, the Middle East, and internationally. The company offers an ultrasound technology that induces coagulation and subsequent revitalization for regenerated skin under the SUPERB brand; and non-invasive muscle toning technology under the Pure Impact VIP brand. It serves plastic surgeons, dermatologists, and other physicians who perform aesthetic treatments on patients. It also provides technical and clinical product support services. The company was incorporated in 2015 and is based in Yokneam Illit, Israel.
SofWave Medical Ltd. management
10- Mr. Louis ScafuriChief Executive Officer · born 1952
- Mr. Assaf Korner CPAChief Financial Officer · born 1977
- Mr. James BartholomeuszChief Innovation Officer · born 1982
- Ms. LIna OmariChief Digital Officer · born 1982
- Mr. Miguel A. PardosChief Commercial Officer · born 1967
- Dr. Shimon Eckhouse Ph.D.Co-Founder & Chairman · born 1945
- Mr. Ariel SverdlikCo-Founder & CTO · born 1969
- Dr. Ruthie AmirChief Medical Officer · born 1965
- Mr. Larry E. LaberExecutive VP of North American Sales · born 1971
- Ms. Tali MalachVice President of Quality · born 1974